The SOX10 protein is widely expressed in normal human tissues including melanocytes and breast tissue. It is also an important marker in malignant tumors such as melanoma, breast carcinoma, gliomas and benign tumors such as schwannomas. SOX10 antibody has been shown to be expressed in 97-100% of desmoplastic and spindle cell melanomas and was also shown to be expressed in 100% of nevi. The majority of oligodendrogliomas but also a large percentage of astrocytomas and poorly differentiated glioblastomas have also been shown to express SOX10. PATENT PENDING.
$160.00 – $1,080.00
1. Mohamed A, et al. SOX10 Expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol. 2013 Dec; 21(6):506-10.
2. Pusch C, et al. The SOX10/Sox10 gene from human and mouse: sequence, expression, and transactivation by the encoded HMG domain transcription factor. Hum Genet. 1998 Aug; 103(2):115-23.
3. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene. 2003 May 19; 22(20):3024-34.
4. Bondurand N, et al. Expression of the SOX10 gene during human development. FEBS Lett. 1998 Aug 7; 432(3):168-72.
5. Bannykh SI, et al. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol. 2006 Jan; 76(2):115-27.
6. Britsch S, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 2001 Jan 1; 15(1):66-78.
7. Feng Z, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992–2007. J Cutan Pathol. 2011 Aug; 38(8):616-24.
8. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
9. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.